Mary Ann Lumiqued

Mary Ann Lumiqued is the VP of Program Management at Tubulis. Mary has over fifteen years of experience in the pharmaceutical industry, including global medical affairs, project management, business planning, and analytics.

Mary Ann started their career at OXiGENE, Inc. in 2008 as an Associate Director of Project Management. In 2010, they joined Ipsen as a Senior Manager of Business Planning and Analytics. Two years later, they were recruited by Acorda Therapeutics as their Director of Project Management. In this role, they were responsible for developing the overall strategy for the company's two commercial products and for the development of new indications.

In 2015, Mary Ann joined MorphoSys as their Global Medical Affairs - Head of Project Strategy and Operations. In this role, they led Medical Affairs operations and drove alignment among external and internal partners in R&D and Commercial. Mary also developed and executed the process for the medical strategy for tafasitamab, felzartamab, pelabresib, and future products.

In their current role as VP of Program Management at Tubulis, Mary Ann is responsible for leading a team of program managers and coordinators who oversee the development and execution of clinical trials for Tubulis' products.

Mary Ann Lumiqued has a B.S. in Animal Physiology and Neuroscience from UC San Diego, and a Professional Award in Biotechnology Management with an Emphasis in Project and Program Management from the University of California, Santa Cruz. Mary is also certified by the Project Management Institute as a Project Management Professional.

Mary Ann Lumiqued reports to Dominik Schumacher, CEO. Mary Ann Lumiqued works with Olivier Marcq - VP, CMC, Jonas Helma-Smets - CSO, and Ingo Lehrke - CBO.